Potential interactions of popular adaptogens (Withania somnifera, Rhodiola rosea) with psychotropic drugs
DOI:
https://doi.org/10.12775/QS.2025.48.67096Keywords
withania, rhodiola, herb-drug interactions, psychotropic drugs, phytotherapyAbstract
Purpose: The aim of this review is to synthesize existing literature regarding the neuropharmacological effects and potential drug interactions of the most commonly used adaptogens: Withania somnifera and Rhodiola rosea; and develop practical guidelines for the safe use of these supplements with psychotropic medications.
Methods: This narrative review examined clinical, observational, and mechanistic studies regarding Ashwagandha and Rhodiola that were identified through a search of PubMed, Cochrane and ScienceDirect between 2013 and 2024.
Results: Ashwagandha has been shown to have significant anxiolytic and stress reducing effects, and has a relatively favorable pharmacokinetic profile. However, it has GABAergic activity which can lead to pharmacodynamic interactions with benzodiazepines, z-drugs, and other central nervous system depressants. Rhodiola, on the other hand, has been shown to have activating and antidepressant-like effects, and has been found to modulate monoaminergic transmission, as well as inhibit the activity of cytochrome P450 enzymes CYP2D6 and CYP3A4. These findings suggest that Rhodiola may increase the risk of serotonin toxicity when combined with certain psychotropic medications, and potentially increase the plasma concentrations of co-administered psychotropics due to decreased metabolic clearance.
Conclusions: Based on the findings of this review, both Ashwagandha and Rhodiola cannot be viewed as pharmacologically inert supplements that can be safely used in conjunction with prescription medications for the treatment of psychiatric disorders. Therefore, they should be carefully assessed prior to initiating therapy, with consideration of the individual's concurrent prescription medications and comorbid medical conditions. Furthermore, they should be initiated at low doses and monitored closely for symptoms of sedation, serotonergic effects, and signs of drug accumulation.
References
1. Anghelescu IG, Edwards D, Seifritz E, Kasper S. Stress management and the role of Rhodiola rosea: a review. Int J Psychiatry Clin Pract. 2018;22(4):242-252.
2. Todorova V, Ivanov K, Delattre C, Nalbantova V, Karcheva-Bahchevanska D, Ivanova S. Plant adaptogens – history and future perspectives. Nutrients. 2021;13(8):2861.
3. Speers AB, Cabey KA, Soumyanath A, Wright KM. Effects of Withania somnifera (ashwagandha) on stress and the stress-related neuropsychiatric disorders anxiety, depression, and insomnia. Curr Neuropharmacol. 2021;19(9):1468-1495.
4. Verma N, Gupta SK, Tiwari S, Mishra AK. Safety of ashwagandha root extract: a randomized, placebo-controlled study in healthy volunteers. Complement Ther Med. 2021;57:102642.
5. Zhang Y, Man Ip C, Lai YS, Zuo Z. Overview of current herb-drug interaction databases. Drug Metab Dispos. 2022;50(1):86-94.
6. Czigle S, Nagy M, Mladěnka P, Tóth J. Pharmacokinetic and pharmacodynamic herb-drug interactions: Part I. Herbal medicines of the central nervous system. PeerJ. 2023;11:e16149.
7. Lacerda GFM, Oliviera PC, Vital MABF, Slomp H Jr, Galduróz JCF, Andreatini R. Phytotherapy in psychiatry: why psychiatrists should know about it. Acta Neuropsychiatr. 2024;36(4):189-194.
8. Maniscalco I. The interaction of Rhodiola rosea and antidepressants: a case report. Neuropsychiatrie. 2015;29(1):36-38. doi:10.1007/s40211-014-0124-8.
9. Pandit S, Srivastav AK, Sur TK, Chaudhuri S, Wang Y, Biswas TK. Effects of Withania somnifera extract in chronically stressed adults: a randomized controlled trial. Nutrients. 2024;16(9):1293.
10. Majeed M, Nagabhushanam K, Mundkur L. A standardized ashwagandha root extract alleviates stress, anxiety, and improves quality of life in healthy adults by modulating stress hormones: results from a randomized, double-blind, placebo-controlled study. Medicine (Baltimore). 2023;102(41):e35521.
11. Wróbel-Biedrawa D, Podolak I. Anti-neuroinflammatory effects of adaptogens: a mini-review. Molecules. 2024;29(4):866.
12. Arumugam V, Vijayakumar V, Balakrishnan A, Bhandari RB, Boopalan D, Ponnurangam R, et al. Effects of ashwagandha (Withania somnifera) on stress and anxiety: a systematic review and meta-analysis. Explore (NY). 2024;20(6):103062. doi:10.1016/j.explore.2024.103062.
13. Tóth-Mészáros A, Garmaa G, Hegyi P, Bánvölgyi A, Fenyves B, Fehérvári P, et al. The effect of adaptogenic plants on stress: a systematic review and meta-analysis. J Funct Foods. 2023;108:105695.
14. Tandon N, Yadav SS. Safety and clinical effectiveness of Withania somnifera (Linn.) Dunal root in human ailments. J Ethnopharmacol. 2020;255:112768.
15. Mandlik Ingawale DS, Namdeo AG. Pharmacological evaluation of ashwagandha highlighting its healthcare claims, safety, and toxicity aspects. J Diet Suppl. 2021;18(2):183-226.
16. Cheng W, Xia K, Wu S, Li Y. Herb-drug interactions and their impact on pharmacokinetics: an update. Curr Drug Metab. 2023;24(1):28-69.
17. Sarris J. Herbal medicines in the treatment of psychiatric disorders: 10-year updated review. Phytother Res. 2018;32(7):1147-1162.
18. Daniel WA, Bromek E, Danek PJ, Haduch A. The mechanisms of interactions of psychotropic drugs with liver and brain cytochrome P450 and their significance for drug effect and drug-drug interactions. Biochem Pharmacol. 2022;199:115006.
19. Xu W, Zhang T, Wang Z, Liu T, Liu Y, Cao Z, Sui Z. Two potent cytochrome P450 2D6 inhibitors found in Rhodiola rosea. Pharmazie. 2013;68(12):974-976.
20. Thu OK, Nilsen OG, Hellum B. In vitro inhibition of cytochrome P450 activities and quantification of constituents in a selection of commercial Rhodiola rosea products. Pharm Biol. 2016;54(12):3249-3256.
21. Amsterdam JD, Panossian AG. Rhodiola rosea L. as a putative botanical antidepressant. Phytomedicine. 2016;23(7):770-783.
22. Pu WL, Zhang MY, Bai RY, Sun LK, Li WH, Yu YL, et al. Anti-inflammatory effects of Rhodiola rosea L.: a review. Biomed Pharmacother. 2020;121:109552.
23. Firenzuoli F, Villa G, Firenzuoli F. Rhodiola rosea L.: potential herbal-drug interactions in perioperative medicine. J Clin Anesth. 2024;97:111544.
24. Juřica J, Koupá T. [Rhodiola rosea and its neuropsychotropic effects]. Ceska Slov Farm. 2016;65(3):87-93.
25. Concerto C, Infortuna C, Muscatello MRA, Bruno A, Zoccali R, Chusid E, et al. Exploring the effect of adaptogenic Rhodiola rosea extract on neuroplasticity in humans. Complement Ther Med. 2018;41:141-146.
26. Gao L, Wu C, Liao Y, Wang J. Antidepressant effects of Rhodiola capsule combined with sertraline for major depressive disorder: a randomized double-blind placebo-controlled clinical trial. J Affect Disord. 2020;265:99-103.
27. Future trends in integrated mental healthcare [Internet]. Elsevier; 2024. Available from: https://www.sciencedirect.com/science/chapter/monograph/abs/pii/B9780443439087000045. Accessed November 10, 2025.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Agata Ogorek, Marta Zasiadła, Paweł Liszka, Klaudia Martyna Parzykąt , Klaudia Maria Olejnik-Chlewicka, Konrad Puchalski, Wojciech Urbański, Jakub Perediatkiewicz, Paweł Mateusz Łuczak, Jakub Brodowski

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 20
Number of citations: 0